Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 12/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.69 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924031 | 0.95 | HDAC3 (0.64) | HDAC3HDAC1NCOR2HDAC6 | |
| SCHEMBL1938429 | 0.82 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL7940675 | 0.82 | KCNQ4 (0.47) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL17538224 | 0.81 | HDAC3 (0.69) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL1938989 | 0.81 | HDAC3 (0.87) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL528531 | 0.81 | HDAC3 (1.00) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL2631173 | 0.79 | HDAC3 (0.76) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL31203495 | 0.79 | HDAC3 (0.54) | HDAC3HDAC1NCOR2 | |
| SCHEMBL7936301 | 0.78 | HDAC3 (0.73) | HDAC3HDAC1NCOR2HDAC2HDAC8 | |
| SCHEMBL24412780 | 0.76 | HDAC6 (0.57) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796664-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2330894-B1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORP (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION | 2016-05-05 | — | — | US | disclosed |
| US-9265734-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2010028192-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | HDAC1, HDAC5, HDAC2 | HDAC3 5/4885HDAC1 1/4885NCOR2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.